IO-202

DB17548InvestigationalProtein Based Therapies

IO-202 is a first-in-class antibody targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) member 4 (LILRB4). It is being investigated in cancers.

Mechanism: Pharmacologically active on Leukocyte immunoglobulin-like receptor subfamily B member 4
Curator reviewed
Code names: IO-202

Resolves to

Targets

Q8NHJ6LILRB4

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with IO-202, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account